AirSculpt Technologies Q4 Earnings Analysis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy AIRS?
Source: seekingalpha
- Disappointing Earnings: AirSculpt Technologies reported a Q4 non-GAAP EPS of -$0.02 with revenues of $33.4 million, reflecting a 14.8% year-over-year decline and missing expectations by $5.5 million, indicating pressure in market competition.
- 2026 Outlook: The company anticipates 2026 revenues between $151 million and $157 million, slightly below the consensus estimate of $153.5 million, reflecting a cautious stance on future growth, with adjusted EBITDA projected at approximately $15 million to $17 million.
- Debt Leverage Target: AirSculpt aims to maintain net debt leverage below 2.5x, a strategic move designed to enhance financial flexibility and reduce risk, supporting future business expansion efforts.
- Market Reaction Analysis: Despite the disappointing financial performance, the company's low valuation may present a buying opportunity for investors, highlighting market interest in its long-term potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AIRS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AIRS
About AIRS
AirSculpt Technologies, Inc., through its wholly owned subsidiaries, is a provider of practice management services to professional associations (PAs) located throughout the United States, Canada, and the United Kingdom. The Company owns and operates non-clinical assets and provides its management services to the PAs through management services agreements (MSAs). It operates through the direct medical procedure services segment. The Company offers fat removal procedures across treatment areas. It also offers fat transfer procedures that use the patient’s own fat cells to enhance the breasts, buttocks, hips, or other areas and do not require silicone or foreign materials to be implanted. Its body contouring procedures include the Power BBL, a Brazilian butt lift procedure, the Up a Cup, a breast enhancement procedure, and the Hip Flip, an hourglass contouring procedure. Its AirSculpt + procedure permanently removes fat and tightens the skin with unparalleled precision and finesse.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AirSculpt Technologies Q4 Earnings Analysis
- Disappointing Earnings: AirSculpt Technologies reported a Q4 non-GAAP EPS of -$0.02 with revenues of $33.4 million, reflecting a 14.8% year-over-year decline and missing expectations by $5.5 million, indicating pressure in market competition.
- 2026 Outlook: The company anticipates 2026 revenues between $151 million and $157 million, slightly below the consensus estimate of $153.5 million, reflecting a cautious stance on future growth, with adjusted EBITDA projected at approximately $15 million to $17 million.
- Debt Leverage Target: AirSculpt aims to maintain net debt leverage below 2.5x, a strategic move designed to enhance financial flexibility and reduce risk, supporting future business expansion efforts.
- Market Reaction Analysis: Despite the disappointing financial performance, the company's low valuation may present a buying opportunity for investors, highlighting market interest in its long-term potential.
See More
AirSculpt Reports Q4 Revenue Decline Amid Strategic Changes
- Revenue Decline: AirSculpt Technologies Inc reported Q4 revenue of $33.4 million, down approximately 15% year-over-year, reflecting challenges in case volume that may impact future market performance.
- Same-Store Sales Drop: Same-store revenue fell by 16% in Q4, indicating difficulties in maintaining consistent sales across existing locations, which could lead to customer attrition and further market share contraction.
- Debt Reduction and Cash Flow: The company paid down $19 million of debt in 2025, ending the year with $56 million in gross debt and $3.1 million in cash flow, although significantly lower than the previous year, it shows ongoing efforts to improve financial health.
- 2026 Outlook: The revenue outlook for 2026 is expected to range from $151 million to $157 million, with adjusted EBITDA projected between $15 million and $17 million, indicating cautious optimism for future growth despite short-term challenges.
See More
AirSculpt Technologies Q4 2025 Earnings Call Insights
- Rebuilding and Transformation: CEO Yogesh Jashnani stated that 2025 was a year of rebuilding and transformation, citing the addition of new talent and processes, strategically exiting the only clinic outside North America to streamline operations and reduce net debt.
- Sales Growth Expectations: Jashnani highlighted GLP-1-related demand as a growth driver for skin tightening, contour restoration, and overall reshaping, with a long-term sales opportunity exceeding $100 million, and plans to expand skin removal surgeries in 2026.
- Financial Performance: CFO Michael Arthur reported Q4 revenue of $33.4 million, down approximately 15% year-over-year, with same-store revenue declining 16%, reflecting challenges in consumer spending, yet achieving a gross margin of about 59% through cost control.
- Future Outlook: Management guided fiscal 2026 revenue between $151 million and $157 million, with adjusted EBITDA of $15 million to $17 million, and no new center openings planned for 2026, focusing efforts on revenue growth in the existing base.
See More
AirSculpt Reports Improved Performance in 2025 Financial Results
- Performance Recovery: In Q4 2025, AirSculpt reported a case volume of 2,604, a 15% decline from Q4 2024, yet adjusted EBITDA improved to $2.5 million from $1.9 million year-over-year, indicating a gradual recovery in profitability amidst challenges.
- Revenue Decline: For the full year 2025, revenue totaled $151.8 million, down 15.8% from $180.4 million in 2024, reflecting pressures from intensified market competition and changing consumer demand impacting overall performance.
- Enhanced Financial Flexibility: As of December 31, 2025, the company had $8.4 million in cash and $5.0 million in borrowing capacity, and raised $14.8 million in Q1 2026 while paying down $11.0 million in debt, reducing total debt to approximately $45.0 million, thereby strengthening its financial foundation for future growth.
- Outlook: The company projects 2026 revenue between $151 million and $157 million, with adjusted EBITDA guidance of $15 million to $17 million, reflecting management's cautious optimism about future performance, particularly as same-store sales show signs of recovery.
See More
AirSculpt to Report Q4 and FY 2025 Results on April 2, 2026
- Earnings Report Schedule: AirSculpt Technologies will announce its fourth quarter and fiscal year 2025 financial results before market open on April 2, 2026, which is expected to provide investors with critical financial data and future outlook.
- Conference Call Details: Following the earnings release, AirSculpt will host a conference call at 8:30 a.m. Eastern Time, where investors can dial 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using conference ID 13758597 to participate.
- Webcast Access: Investors can access the earnings release webcast via the investor relations section of AirSculpt's website, with a replay available for approximately 90 days, ensuring that investors can stay informed at their convenience.
- Company Overview: AirSculpt is a next-generation body contouring treatment designed for comfort and precision, utilizing minimally invasive procedures to remove fat and tighten skin, allowing for quick healing and precise results, thereby enhancing the company's competitive edge in the premium body sculpting market.
See More
NASDAQ 100 Pre-Market Indicator Rises Significantly
- Market Indicator Surge: The NASDAQ 100 Pre-Market Indicator rises by 266.97 points to 24,647.7, indicating a positive shift in market sentiment that may attract more investors to tech stocks.
- Active Stock Performance: CytomX Therapeutics, Inc. (CTMX) increases by $2.34 to $7.02 with a trading volume of 27,793,236 shares, reflecting optimistic short-term prospects for the company.
- ETF Trading Dynamics: ProShares UltraPro QQQ (TQQQ) climbs $1.46 to $47.39 with 6,584,506 shares traded, representing a 170.8% increase from its 52-week low, showcasing strong investor interest in tech stocks.
- Earnings Forecast Revisions: Circle Internet Group, Inc. (CRCL) rises $5.795 to $121.18, with an expected EPS of $0.22 for the fiscal quarter ending September 2026, indicating market confidence in its future profitability.
See More
AirSculpt Technologies Q4 Earnings Analysis
- Disappointing Earnings: AirSculpt Technologies reported a Q4 non-GAAP EPS of -$0.02 with revenues of $33.4 million, reflecting a 14.8% year-over-year decline and missing expectations by $5.5 million, indicating pressure in market competition.
- 2026 Outlook: The company anticipates 2026 revenues between $151 million and $157 million, slightly below the consensus estimate of $153.5 million, reflecting a cautious stance on future growth, with adjusted EBITDA projected at approximately $15 million to $17 million.
- Debt Leverage Target: AirSculpt aims to maintain net debt leverage below 2.5x, a strategic move designed to enhance financial flexibility and reduce risk, supporting future business expansion efforts.
- Market Reaction Analysis: Despite the disappointing financial performance, the company's low valuation may present a buying opportunity for investors, highlighting market interest in its long-term potential.
See More
AirSculpt Reports Q4 Revenue Decline Amid Strategic Changes
- Revenue Decline: AirSculpt Technologies Inc reported Q4 revenue of $33.4 million, down approximately 15% year-over-year, reflecting challenges in case volume that may impact future market performance.
- Same-Store Sales Drop: Same-store revenue fell by 16% in Q4, indicating difficulties in maintaining consistent sales across existing locations, which could lead to customer attrition and further market share contraction.
- Debt Reduction and Cash Flow: The company paid down $19 million of debt in 2025, ending the year with $56 million in gross debt and $3.1 million in cash flow, although significantly lower than the previous year, it shows ongoing efforts to improve financial health.
- 2026 Outlook: The revenue outlook for 2026 is expected to range from $151 million to $157 million, with adjusted EBITDA projected between $15 million and $17 million, indicating cautious optimism for future growth despite short-term challenges.
See More
AirSculpt Technologies Q4 2025 Earnings Call Insights
- Rebuilding and Transformation: CEO Yogesh Jashnani stated that 2025 was a year of rebuilding and transformation, citing the addition of new talent and processes, strategically exiting the only clinic outside North America to streamline operations and reduce net debt.
- Sales Growth Expectations: Jashnani highlighted GLP-1-related demand as a growth driver for skin tightening, contour restoration, and overall reshaping, with a long-term sales opportunity exceeding $100 million, and plans to expand skin removal surgeries in 2026.
- Financial Performance: CFO Michael Arthur reported Q4 revenue of $33.4 million, down approximately 15% year-over-year, with same-store revenue declining 16%, reflecting challenges in consumer spending, yet achieving a gross margin of about 59% through cost control.
- Future Outlook: Management guided fiscal 2026 revenue between $151 million and $157 million, with adjusted EBITDA of $15 million to $17 million, and no new center openings planned for 2026, focusing efforts on revenue growth in the existing base.
See More
AirSculpt Reports Improved Performance in 2025 Financial Results
- Performance Recovery: In Q4 2025, AirSculpt reported a case volume of 2,604, a 15% decline from Q4 2024, yet adjusted EBITDA improved to $2.5 million from $1.9 million year-over-year, indicating a gradual recovery in profitability amidst challenges.
- Revenue Decline: For the full year 2025, revenue totaled $151.8 million, down 15.8% from $180.4 million in 2024, reflecting pressures from intensified market competition and changing consumer demand impacting overall performance.
- Enhanced Financial Flexibility: As of December 31, 2025, the company had $8.4 million in cash and $5.0 million in borrowing capacity, and raised $14.8 million in Q1 2026 while paying down $11.0 million in debt, reducing total debt to approximately $45.0 million, thereby strengthening its financial foundation for future growth.
- Outlook: The company projects 2026 revenue between $151 million and $157 million, with adjusted EBITDA guidance of $15 million to $17 million, reflecting management's cautious optimism about future performance, particularly as same-store sales show signs of recovery.
See More
AirSculpt to Report Q4 and FY 2025 Results on April 2, 2026
- Earnings Report Schedule: AirSculpt Technologies will announce its fourth quarter and fiscal year 2025 financial results before market open on April 2, 2026, which is expected to provide investors with critical financial data and future outlook.
- Conference Call Details: Following the earnings release, AirSculpt will host a conference call at 8:30 a.m. Eastern Time, where investors can dial 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using conference ID 13758597 to participate.
- Webcast Access: Investors can access the earnings release webcast via the investor relations section of AirSculpt's website, with a replay available for approximately 90 days, ensuring that investors can stay informed at their convenience.
- Company Overview: AirSculpt is a next-generation body contouring treatment designed for comfort and precision, utilizing minimally invasive procedures to remove fat and tighten skin, allowing for quick healing and precise results, thereby enhancing the company's competitive edge in the premium body sculpting market.
See More
NASDAQ 100 Pre-Market Indicator Rises Significantly
- Market Indicator Surge: The NASDAQ 100 Pre-Market Indicator rises by 266.97 points to 24,647.7, indicating a positive shift in market sentiment that may attract more investors to tech stocks.
- Active Stock Performance: CytomX Therapeutics, Inc. (CTMX) increases by $2.34 to $7.02 with a trading volume of 27,793,236 shares, reflecting optimistic short-term prospects for the company.
- ETF Trading Dynamics: ProShares UltraPro QQQ (TQQQ) climbs $1.46 to $47.39 with 6,584,506 shares traded, representing a 170.8% increase from its 52-week low, showcasing strong investor interest in tech stocks.
- Earnings Forecast Revisions: Circle Internet Group, Inc. (CRCL) rises $5.795 to $121.18, with an expected EPS of $0.22 for the fiscal quarter ending September 2026, indicating market confidence in its future profitability.
See More
